Compare RGP & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | GNLX |
|---|---|---|
| Founded | 1996 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.0M | 113.6M |
| IPO Year | 2000 | 2022 |
| Metric | RGP | GNLX |
|---|---|---|
| Price | $4.49 | $2.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 259.7K | 158.2K |
| Earning Date | 04-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.85% | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $551,331,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.06 | $2.29 |
| 52 Week High | $6.07 | $8.54 |
| Indicator | RGP | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 64.72 | 54.70 |
| Support Level | $4.22 | $2.39 |
| Resistance Level | $4.52 | $2.97 |
| Average True Range (ATR) | 0.18 | 0.23 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 82.28 | 40.74 |
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.